SIR-Spheres® Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting

Friday 13 June 2008
Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 2008 Society of Nuclear Medicine (SNM) Annual Meeting. The meeting, to be held June 14-18 at the Convention Center in New Orleans, La., is considered the premier educational and scientific event in the nuclear medicine community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has metastasized to the liver.

The scientific program includes a CME session entitled Liver-Directed Radiomicrosphere Therapy: Advances and Opportunities for Nuclear Medicine. Organized and moderated by Seza Gulec, M.D., F.A.C.S. and the Nuclear Oncology Council of SNM, the program is designed to review the techniques and clinical applications of Selective Internal Radiation Therapy (SIRT) in the management of metastatic liver cancers.

This CME symposium will discuss the scientific basis of microsphere therapy, clinical indications, patient selection, imaging protocols for disease assessment and patient follow-up, treatment planning and dosimetry. New data regarding ongoing clinical trials with SIR-Spheres microspheres will also be featured.

“Sirtex is proud to support SNM and its mission to improve cancer care and prevention and ensure that all patients with liver metastases receive the highest quality of care,” says Dr. John Reddington, President of Sirtex Medical.

Sirtex Medical Inc.’s SIR-Spheres microspheres are indicated for the treatment of non- resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer-reviewed literature may differ from the approved USA indications as per the labeling for the product.

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally- invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA approval), and the European Union (CE Mark) and additionally supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel and Turkey with more than 7,500 patients having been treated to date.

For more information, visit


SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd


Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage